Literature DB >> 7784081

The proto-oncogene FGF-3 is constitutively expressed in tumorigenic, but not in non-tumorigenic, clones of a human colon carcinoma cell line.

C Galdemard1, O Brison, C Lavialle.   

Abstract

The human colon carcinoma cell line, SW613-S, is composed of cells with a high-level amplification of the MYC proto-oncogene that are tumorigenic in nude mice and of cells with a low-level amplification of MYC that are not tumorigenic. Transcripts from FGF-3, a member of the fibroblast growth factor gene family, accumulate in cells from tumorigenic clones, but are undetectable in those from non-tumorigenic clones. Nuclear run-on analyses indicate that this differential FGF-3 expression is regulated at the level of transcription initiation. Determination of the structure of the FGF-3 transcripts indicates that they are generated by splicing of the three exons and termination at the single polyadenylation site predicted from the genomic sequence. Their size heterogeneity is due to multiple initiation sites spanning a 700 base-pair long promoter region. FGF-3 is activated in tumors induced in nude mice by MYC-transfected cells from non-tumorigenic clones. However, in most of the cell lines established from these tumors, FGF-3 expression tends to be lost upon in vitro propagation. Thus, in these transfectant cell lines, the presence of exogenous MYC gene copies is not sufficient to activate FGF-3 expression and in vivo growth is also required.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7784081

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

Review 1.  Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis.

Authors:  Christopher Lieu; John Heymach; Michael Overman; Hai Tran; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2011-09-27       Impact factor: 12.531

2.  Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.

Authors:  Thomas Bachleitner-Hofmann; Mark Y Sun; Chin-Tung Chen; David Liska; Zhaoshi Zeng; Agnes Viale; Adam B Olshen; Martina Mittlboeck; James G Christensen; Neal Rosen; David B Solit; Martin R Weiser
Journal:  Clin Cancer Res       Date:  2011-01-01       Impact factor: 12.531

3.  Phenotypic consequences of lung-specific inducible expression of FGF-3.

Authors:  B Zhao; S S Chua; M M Burcin; S D Reynolds; B R Stripp; R A Edwards; M J Finegold; S Y Tsai; F J DeMayo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-01       Impact factor: 11.205

4.  Transcriptional deregulation of the keratin 18 gene in human colon carcinoma cells results from an altered acetylation mechanism.

Authors:  Philippe Prochasson; Cécile Delouis; Olivier Brison
Journal:  Nucleic Acids Res       Date:  2002-08-01       Impact factor: 16.971

5.  High frequency trans-splicing in a cell line producing spliced and polyadenylated RNA polymerase I transcripts from an rDNA-myc chimeric gene.

Authors:  Célia Chen; Nicole Fossar; Dominique Weil; Marine Guillaud-Bataille; Gisèle Danglot; Brigitte Raynal; François Dautry; Alain Bernheim; Olivier Brison
Journal:  Nucleic Acids Res       Date:  2005-04-22       Impact factor: 16.971

6.  Use of adenoviral E1A protein to analyze K18 promoter deregulation in colon carcinoma cells discloses a role for CtBP1 and BRCA1.

Authors:  Cécile Delouis; Philippe Prochasson; Madeleine Laithier; Olivier Brison
Journal:  BMC Mol Biol       Date:  2005-04-14       Impact factor: 2.946

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.